免疫疗法
肺癌
嵌合抗原受体
过继性细胞移植
T细胞
癌症
癌症免疫疗法
免疫学
细胞疗法
癌症研究
免疫系统
医学
免疫检查点
肿瘤科
生物
细胞
内科学
遗传学
作者
Yutao Li,Amit Sharma,Ingo G. H. Schmidt‐Wolf
标识
DOI:10.1186/s12943-023-01926-4
摘要
Abstract Undeniably, cancer immunotherapies have expanded the spectrum of cancer treatment, however, some patients do not respond to immunotherapies. This scenario is no different for lung cancer, whose two main types, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), still pose a serious clinical challenge. Adoptive T-cell therapies (ATC), which primarily include cytokine-induced killer (CIK) cell therapy, chimeric antigen receptor T-cell (CAR T-cell) therapy and γδ-T-cell therapy, strengthen the patient’s immune system in combating cancer. Combining ATC with immune checkpoint inhibitors (ICI) further enhances the effectiveness of this approach to eradicate cancer. With a particular emphasis on CIK cell therapy, which recently completed 30 years, we highlight the role of the PD-1/PD-L1 axis in NSCLC and SCLC. Besides, we provide insights into the potential synergies of PD-1/PD-L1 inhibitors with adoptive T-cell immunotherapy in reshaping the treatment paradigm for lung cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI